I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASHSOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the ...

EFX is now being further evaluated in three ongoing Phase 3 trials targeting all stages of MASH. EFX, Akero's lead candidate, is an FGF21 analog designed for once-weekly dosing.

Equifax faces growth headwinds, premium valuation, and flat price action despite AI and cloud investments, with limited ...

Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with ...

Equifax Inc. Annual stock financials by MarketWatch. View the latest EFX financial statements, income statements and financial ratios.

EFX continues to strive to bring you prop replicas of the highest level of authenticity and accuracy possible. This edition is no different, it utilizes parts cast from the same master patterns ...